These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn's disease. Bodini G; Giannini EG; Savarino V; Del Nero L; Pellegatta G; De Maria C; Baldissarro I; Savarino E Scand J Gastroenterol; 2016 Sep; 51(9):1081-6. PubMed ID: 27207330 [TBL] [Abstract][Full Text] [Related]
8. Adalimumab for endoscopic and histopathological mucosal healing in paediatric patients with moderate to severe Crohn's disease. Szymanska E; Dadalski M; Grajkowska W; Szymanska S; Pronicki M; Kierkus J Prz Gastroenterol; 2017; 12(1):44-48. PubMed ID: 28337236 [TBL] [Abstract][Full Text] [Related]
9. Comparative Effectiveness of Ustekinumab Versus Adalimumab in Induction of Clinical Response and Remission in Crohn's Disease: Experience of a Real-World Cohort at a Tertiary Care Inflammatory Bowel Disease Referral Center. Ahmed Z; Venkata K; Zhang N; Malik TA Gastroenterology Res; 2019 Oct; 12(5):245-251. PubMed ID: 31636774 [TBL] [Abstract][Full Text] [Related]
10. Distinct alterations of fecal microbiota refer to the efficacy of adalimumab in Crohn's disease. Chen L; Lu Z; Kang D; Feng Z; Li G; Sun M; Liu Z; Wu W; Fang L Front Pharmacol; 2022; 13():913720. PubMed ID: 36034848 [No Abstract] [Full Text] [Related]
11. Association between serum adalimumab concentrations and endoscopic disease activity in patients with Crohn's disease. Morita Y; Imaeda H; Nishida A; Inatomi O; Bamba S; Sasaki M; Tsujikawa T; Sugimoto M; Andoh A J Gastroenterol Hepatol; 2016 Nov; 31(11):1831-1836. PubMed ID: 27043158 [TBL] [Abstract][Full Text] [Related]
12. Long-Term Clinical Remission in Biologically Naïve Crohn's Disease Patients with Adalimumab Therapy, Including Analyses of Switch from Adalimumab to Infliximab. Mizoshita T; Tanida S; Ozeki K; Katano T; Shimura T; Mori Y; Kubota E; Kataoka H; Kamiya T; Joh T Case Rep Gastroenterol; 2016; 10(2):283-91. PubMed ID: 27462198 [TBL] [Abstract][Full Text] [Related]
13. Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease. Battat R; Kopylov U; Bessissow T; Bitton A; Cohen A; Jain A; Martel M; Seidman E; Afif W Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1427-1434.e2. PubMed ID: 28365485 [TBL] [Abstract][Full Text] [Related]
14. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Roblin X; Marotte H; Rinaudo M; Del Tedesco E; Moreau A; Phelip JM; Genin C; Peyrin-Biroulet L; Paul S Clin Gastroenterol Hepatol; 2014 Jan; 12(1):80-84.e2. PubMed ID: 23891927 [TBL] [Abstract][Full Text] [Related]
15. Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn's disease. Imaeda H; Takahashi K; Fujimoto T; Bamba S; Tsujikawa T; Sasaki M; Fujiyama Y; Andoh A J Gastroenterol; 2014 Jan; 49(1):100-9. PubMed ID: 23575576 [TBL] [Abstract][Full Text] [Related]
16. Combination Therapy with Intensive Granulocyte and Monocyte Adsorptive Apheresis plus Adalimumab: Therapeutic Outcomes in 5 Cases with Refractory Crohn's Disease. Ozeki K; Tanida S; Mizoshita T; Tsukamoto H; Ebi M; Mori Y; Kataoka H; Kamiya T; Joh T Case Rep Gastroenterol; 2012 Sep; 6(3):765-71. PubMed ID: 23341799 [TBL] [Abstract][Full Text] [Related]
17. Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease. Gordon M; Taylor K; Akobeng AK; Thomas AG Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD010233. PubMed ID: 25081347 [TBL] [Abstract][Full Text] [Related]
18. Therapeutic monitoring of adalimumab at non-trough levels in patients with inflammatory bowel disease. Kato M; Sugimoto K; Ikeya K; Takano R; Matsuura A; Miyazu T; Ishida N; Tamura S; Tani S; Yamade M; Hamaya Y; Iwaizumi M; Osawa S; Furuta T; Hanai H PLoS One; 2021; 16(7):e0254548. PubMed ID: 34242369 [TBL] [Abstract][Full Text] [Related]
19. Relationship between Serum Adalimumab Levels and Clinical Outcome in the Treatment of Inflammatory Bowel Disease. Hinojosa J; Muñoz F; Martínez-Romero GJ Dig Dis; 2019; 37(6):444-450. PubMed ID: 31039560 [TBL] [Abstract][Full Text] [Related]
20. Adalimumab Treatment in Biologically Naïve Crohn's Disease: Relationship with Ectopic MUC5AC Expression and Endoscopic Improvement. Mizoshita T; Tanida S; Tsukamoto H; Ozeki K; Katano T; Nishiwaki H; Ebi M; Mori Y; Kubota E; Kataoka H; Kamiya T; Joh T Gastroenterol Res Pract; 2014; 2014():687257. PubMed ID: 24829572 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]